Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Amivantamab and hyaluronidase-lpuj |
| Trade Name | Rybrevant Faspro |
| Synonyms | |
| Drug Descriptions |
Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) is a subcutaneous formulation of amivantamab, which may lead to improved tolerability and convenience (PMID: 38857463). Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) is FDA-approved for use in all indications approved for the intravenous formulation of Rybrevant (amivantamab-vmjw) (FDA.gov). |
| DrugClasses | EGFR Antibody 74 EGFR Exon 20 Insertion Inhibitor 16 MET Antibody 39 |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Amivantamab and hyaluronidase-lpuj | Amivantamab and hyaluronidase-lpuj | 0 | 0 |